Vasculopathy, Behcet's syndrome, and familial Mediterranean fever

Current Opinion in Rheumatology

Volumn 11, Issue 5, 1999, Pages 393-398

  Ozen, Seza ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN; SUPERANTIGEN;

ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; BEHCET DISEASE; FAMILIAL MEDITERRANEAN FEVER; GENETIC DISORDER; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VASCULAR DISEASE; GENETICS; IMMUNOLOGY; VASCULITIS;

BEHCET SYNDROME; FAMILIAL MEDITERRANEAN FEVER; HUMANS; SUPERANTIGENS; VASCULITIS;

EID: 0032589317     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199909000-00011     Document Type: Review

References (36)

1. Gerber O: Vasculitis owing to infection. Neurol Clin 1997, 15:903-925.
2. Tervaert JWC, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 1999, 11:24-33. This article is a thorough review of the role of microbial superantigens in different forms of vasculitis.
3. Bont K, Brus F, Dijkman-Neerincx RH, Jansen TL, Meyer JW, Janssen M: The clinical spectrum of post-streptococcal syndrome with arthrits in children. Clin Exp Rheumatol 1998, 16:750-752.
4. Abe Y, Nakano S, Aita K, Sagishima M: Streptococcal and staphylococcal superantigen-induced lymphocytic arteritis in a local type experimental model: comparison with acute vasculitis in the Arthus reaction. J Lab Clin Med 1998, 131:93-102. To elucidate whether superantigenic exotoxins are able to induce vasculitis, a local-type experimental model was designed in rabbits. Vasculitis was demonstrated after injection of Streptococcal and staphylococcal toxins.
5. Leung DYM, Sullivan KE, Brown-Whitehorn TF, Fehringer AP, Allen S, Finkel TH et al: Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr Res 1997, 42:268-272.
6. Yanagawa H, Nakakmura Y, Yashiro M, Ojima Y, Tanihira S, Oki I, Zhang T: Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatr 1998, 102:E65.
7. Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M: Leukocyte counts in patients with Kawasaki disease: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 1997, 86:1328-1332.
8. Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW: Kawasaki disease in the older child. Pediatr 1998, 102:e7.
9. Hahn D, Thomson PD, Kala U, Beale PG, Levin SE: A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr Nephrol 1998, 12:668-675.
10. Murakami K, Ohsawa M, Hu S-X, Kanno H, Aozasa K, Nose M: Large vessel arteritis associated with chronic active Epstein-Barr virus infection. Arthritis Rheum 1998, 41:369-373.
11. Gattorno m, Picco P, Barbano G, Stalla F, Sormani MP, Bouuncompagni A, Gusmano R, Borrone C, Pistoia V: Differences in TNF soluble receptor serum concentrations between patients with HSP and pediatric SLE: pathogenic implications. J Rheumatol 1998, 25:361-365.
12. Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, Bakkaoglu A, Elnahas AM: The role of cytokines in HSP. Scand J Rheumatol 1997, 26:456-460.
13. Rostoker G, Rymer JC, Bagnard G, Petit-Phar M, Griuncelli M, Pilatte Y: Imbalances in serum pro-inflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy and Henoch Schonlein purpura nephritis and a potential target of immunoglobulin therapy. Clin Exp Immunol 1998, 114:468-476.
14. Dillon MJ: Childhood vasculitis. Lupus 1998, 7:259-265.
15. Ehrlich GE: Behçet Disease and the emergence of thalidomide. Ann Int Med 1998, 128:494-495.
16. Yazici H, Yurdakul S, Hamuryudan V: Behçet's syndrome. Curr Opin Rheumatol 1999, 11:53-7. This is an extensive review of Behçet's syndrome.
17. Kaneko F, Oyama N, Nisibu A: Streptococcal infection in the pathogenesis of Behçet's syndrome and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997, 38:444-454.
18. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I: Effect of prophylactic benzathine penicilin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996, 192:125-128.
19. Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, Bernard JL: Epidemiological features of Behçet's syndrome in children: an international collaborative survey of 86 cases. J Pediatr 1998, 135:721-725. This study provides important data for the clinical features of Behçet's syndrome in children.
20. Uziel Y, Brik R, Padeh S, Barash J, Mukamel M, Harel L, Press J, Tauber T, Rakover Y, Wolach B: Juvenile Behçet's syndrome in Israel. Clin Exp Rheumatol 1998, 16:502-505.
21. Eldem B, Onur C, Ozen S: Clinical features of pediatric Behçet's disease. J Pediatr Ophthalmol Strabismus 1998, 35:159-161.
22. Fresko I, Soy M, Hamuryudan V, Yurdakul S, Yavuz S, Tumer Z, Yazici H: Genetic anticipation in Behçet's syndrome. Ann Rheum Dis 1998, 57:45-48.
23. Akpolat T: Management of the patient with Behçet's disease. Nephrol Dial Transplant 1998, 13:3002-3004.
24. Kastner DL: FMF: the genetics of inflammation. Hosp Prac 1998, 33:131-158. This paper presents novel suggestions and conclusions for FMF and inflammation. It is a paper by a pioneer of the field.
25. Ben-Chetrit E, Lovy M: FMF. Lancet 1998, 351:659-664. This is a concise review of FMF, reviewing important practical points regarding the disease.
26. Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z. Sood R, Kastner DL: FMF at the Millennium: clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 1998, 77:268-297. This paper deserves special merit not just for being an update review, but also for the excellent figures explaining the molecular basis of FMF.
27. Ozen S, Karaasan Y, Ozdemir O, Saatci U, Bakkaloglu A, Tezcan S: Prevalence of juvenile chronic arthritis and familial mediterranean fever in Turkey: a field study. J Rheumatol 1998, 25:2445-2449.
28. Grateau G: FMF: from inflammation to amyloidosis. Nephrol Dial Transplant 1998, 13:1919-1920.
29. Dewalle M, Domingo C, Rozenbaum M, Ben-Chetrit E, Cattan D, Bernoat A, Dross C, Dupont M, Notarnicola C, Levy M, Rosner I, Demaille J, Touitou J: Phenotype-genotype correlation in Jewish patients suffering from FMF. Eur J Hum Genet 1998, 6:95-97.
30. Shohat M, Lotan R, Magal N, Danon Y, Ogur G, Tokgoz G, Schlezinger M, Schwabe A, Halpern G, Fisccel-Ghodsian N, Kastner D, Shohat T, Rotter JI: Amyloidosis in FMF is associated with a specific ancestral haplotype in the MEFV locus. Mol Genet Metab 1998, 65:197-202.
31. Saatci U, Bakkaloglu A, Ozen S, Besbas N: Familial Mediterranean fever and amyloidosis in children. Acta Paediatrica 1993, 81:705-706.
32. Akpolat T, Yilmaz E, Ozen S, Akpolat I, Danaci M, Kandemir B: M6801/M694V mutations in a patient with FMF and polyarteritis nodosa. Nephrol Dial Transplant 1998, 13:2633-2635.
33. McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA, McCarhty J, Phelan M, Moleyu MG, Oowell RJ, Amos CI, Hitman GA: Linkage of familial hibernian fever to chromosome 12p13. Am J Hum Genet 1998, 62:1446-1451.
34. Mulley J, Saar K, Hewitt G, Ruschendorf F, Philips H, Colley A, Sillence D, Reis A, Wilson M: Gene localisation for a autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 1998, 62:884-889.
35. McDermott MF, Aksentijevich I, Galon J, McDermott E, Ogunkolade BW, Centola M, et al: Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
36. Ben-Chetrit E, Levy M: Colchicine: 1998 update. Semin Arthr Rheum 1998, 28:48-59.